We are live on ! Find out more
SABSW icon

SAB Biotherapeutics Warrant
SABSW

21 hedge funds and large institutions have $3.86M invested in SAB Biotherapeutics Warrant in 2021 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 9 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

4% less capital invested

Capital invested by funds: $4.04M → $3.86M (-$178K)

13% less funds holding

Funds holding: 24 → 21 (-3)

30% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 10

56% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 9

Holders
21
Holders Change
-3
Holders Change %
-12.5%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
4
Reduced
9
Closed
10
Calls
$2.34M
Puts
–
Net Calls
+$2.34M
Net Calls Change
+$2.28M

Top Buyers

Rank Fund Capital Flow
1
SCM
Shaolin Capital Management
Florida
+$840K
2
FBCM
Fort Baker Capital Management
California
+$67.3K
3
Morgan Stanley
Morgan Stanley
New York
+$57.6K
4
CCM
Context Capital Management
California
+$43K
5
BCM
Bluefin Capital Management
New York
+$35.3K

Top Sellers

Rank Fund Capital Flow
1
OCAM
Owl Creek Asset Management
New York
-$242K
2
CH
CVI Holdings
Delaware
-$214K
3
KC
Kepos Capital
New York
-$183K
4
RCM
Radcliffe Capital Management
Pennsylvania
-$171K
5
PAMP
Polar Asset Management Partners
Ontario, Canada
-$161K
Name Holding Trade Value Shares
Change 		Change in
Stake
UOC
26
UBS O'Connor
Illinois
– -$116K -124,996 Closed
GCL
27
Glazer Capital LLC
New York
– -$108K -117,505 Closed
BCM
28
Basso Capital Management
Connecticut
– -$80K -87,475 Closed
AA
29
AQR Arbitrage
Connecticut
– -$45K -50,000 Closed
PC
30
Periscope Capital
Ontario, Canada
– -$28K -30,647 Closed
EAM
31
Exos Asset Management
New York
– -$25K -27,500 Closed
TRCT
32
Tower Research Capital (TRC)
New York
– +$88 +48 New
1
2

SABSW Hedge Fund Activity: Q4 2021 in Review

21 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics Warrant (SABSW) for Q4 2021, worth a combined $3.86M — down 4.4% from $4.04M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of SABSW and 7 opened new positions — a net loss of 3 holders — while 9 trimmed existing stakes and 4 added.

The largest buyer was Shaolin Capital Management, adding an estimated $840K. The largest seller was Owl Creek Asset Management, exiting entirely with an estimated $242K sold.

  • 21 institutional investors held SAB Biotherapeutics Warrant (SABSW) as of Q4 2021, down from 24 in Q3 2021.
  • Funds reported $3.86M of SAB Biotherapeutics Warrant stock for Q4 2021, down 4.4% quarter-over-quarter.
  • 7 funds opened new SAB Biotherapeutics Warrant positions in Q4 2021 and 10 closed out, a net change of -3 holders.
  • The largest SAB Biotherapeutics Warrant buyer in Q4 2021 was Shaolin Capital Management, an estimated $840K added.
  • The largest SAB Biotherapeutics Warrant seller in Q4 2021 was Owl Creek Asset Management, an estimated $242K sold.

Based on aggregated 13F filings for Q4 2021.